-
Publication Venue For
-
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer..
31:590-598.
2020
-
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study..
29:154-161.
2018
-
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.
28:2517-2525.
2017
-
ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia..
28:1949-1956.
2017
-
A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer.
27:vi556.
2016
-
A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC).
27:vi565.
2016
-
Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC).
27:vi493.
2016
-
Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial.
27:vi262.
2016
-
Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma.
27:vi379.
2016
-
Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression.
27:vi366.
2016
-
Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP).
27:vi243.
2016
-
Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021.
27:vi483.
2016
-
breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).
27:vi553.
2016
-
Corrigendum to Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram [Ann Oncol 26, (2015) 1930-1935] doi: 10.1093/annonc/mdv279.
27:753.
2016
-
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors [Ann Oncol, 26, (2015), 2125-2132] doi: 10.1093/annonc/mdv310.
26:2507-2508.
2015
-
RE: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.
25:1670-1671.
2014
-
CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon.
25:ii112.
2014
-
Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial.
25:ii115.
2014
-
Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'..
18 Suppl 10:x1-x2.
2007
-
Treatment options in renal cell carcinoma: past, present and future..
18 Suppl 10:x25-x31.
2007
-
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma..
18:1216-1223.
2007
-
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804..
18:1071-1079.
2007
-
Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902..
18:331-337.
2007
-
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials..
17:1749-1760.
2006
-
Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference..
17:1615-1619.
2006
-
Molecular imaging in oncology..
17 Suppl 10:x287-x292.
2006
-
Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer..
17:986-989.
2006
-
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors..
16:1391-1397.
2005
-
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials..
16:558-565.
2005
-
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer..
16:579-584.
2005
-
Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study..
15:1173-1178.
2004
-
Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity..
15:1033-1041.
2004
-
Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate..
15:974-978.
2004
-
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC..
15:410-418.
2004
-
Pegfilgrastim: the promise of pegylation fulfilled..
14:6-7.
2003
-
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study..
13:1576-1582.
2002
-
A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer..
13:435-440.
2002
-
Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients..
13:258-266.
2002
-
Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study..
13:95-102.
2002
-
Evaluation and appraisal of randomized controlled trials in myeloma..
12:1611-1617.
2001
-
Systematic esophageal endoscopy screening in patients previously treated for head and neck squamous-cell carcinoma..
12:643-646.
2001
-
The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study..
12:633-641.
2001
-
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study..
12:535-540.
2001
-
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies..
11:1313-1322.
2000
-
Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B..
11:1141-1146.
2000
-
A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL..
11:691-695.
2000
-
Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer..
11:229-230.
2000
-
Phase I study of Doxil and vinorelbine in metastatic breast cancer..
10:1113-1116.
1999
-
Recent advances in the treatment of prostate cancer..
10:891-898.
1999
-
High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234..
10:597-600.
1999
-
Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors..
9:1003-1008.
1998
-
Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B..
9:297-306.
1998
-
Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111In-pentetreotide scan..
9:213-216.
1998
-
The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy..
8:1117-1124.
1997
-
Paraneoplastic temporal lobe epilepsy and anti-Yo autoantibody..
8:919.
1997
-
One and a half decades of the Lugano International Conference on Malignant Lymphoma: variations on a theme or true progress?.
8 Suppl 1:1-3.
1997
-
The sixth Lugano conference: Basic science papers.
8.
1997
-
Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia..
6:300-301.
1995
-
Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma..
5:468-470.
1994
-
Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma..
5:286-287.
1994
-
Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B..
3:727-732.
1992
-
Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin..
2:519-520.
1991
-
The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data..
2 Suppl 1:47-50.
1991
-
381MO Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
2020
-
83MO AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 phase I trial
2020
-
1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
2020
-
1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma
2020
-
523TiP MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer
2020
-
635P ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels
2020
-
665P Impact of enzalutamide on patient-reported fatigue in hormone-sensitive prostate cancer (HSPC) or castration-resistant prostate cancer (CRPC)
2020
-
705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)
2020
-
883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer
2020
-
884TiP AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer
2020
-
SO-24 AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: Results from the CodeBreak 100 phase 1 trial
2020
-
A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
2019
-
A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer
2019
-
ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
2019
-
BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study
2019
-
Cell-Free DNA to detect focal versus non-focal MET amplification in metastatic colorectal cancer patients: Combined analysis from Japan and the United States
2019
-
Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD
2019
-
Expression of x-linked inhibitor of apoptosis protein (XIAP) and its association with clinicopathological parameters in invasive breast cancers
2019
-
Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
2019
-
Implementing a cancer survivorship program for individuals with recurrent breast cancer
2019
-
Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours
2019
-
Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours
2019
-
STING agonist, ADU-S100, yields potent anti-tumour activity and therapeutically favorable immune profile in an esophageal adenocarcinoma model
2019
-
Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial
2019
-
A phase 1b/2 study of omaveloxolone in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma
2017
-
A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival
2017
-
AGITG NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas
2017
-
Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer
2017
-
Dual CDK 4/6 inhibitor demonstrates potent antitumor efficacy in vitro and in vivo against esophageal adenocarcinoma
2017
-
KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC)
2017
-
Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC)
2017
-
Prognostic associations of prostate-specific antigen (PSA) decline with survival, radiographic response and progression in chemotherapy-naiive men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide
2017
-
Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
2017
-
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)
2017
-
QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)
2017
-
Impact of the sterol 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol on tumor-pathological features, prognosis and response to statin treatment in breast cancer
2017
-
Comparison of chemoradiotherapy treatment strategies in stage III non-small cell lung cancer among elderly patients from multiple data sources
2017
-
A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours
2016
-
A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer
2016
-
A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma
2016
-
A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study
2016
-
A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)—CheckMate-548
2016
-
A randomized phase II study of leucovorin, 5-fluorouracil with or without oxaliplatin (LV5FU2 vs. FOLFOX) for curatively-resected, node-positive esophageal squamous cell carcinoma
2016
-
CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial
2016
-
Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)
2016
-
First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors
2016
-
Impact of chemotherapy-induced nausea and vomiting (CINV) on emergency department (ED) visits and disruption of chemotherapy: results of a survey of oncology nurses
2016
-
Influence of diabetes and congestive heart failure (CHF) on selection of first-line (1L) treatment for metastatic renal cell carcinoma (mRCC)
2016
-
Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update
2016
-
METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC)
2016
-
Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)
2016
-
Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study
2016
-
Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study
2016
-
genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)
2016
-
Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ)
2016
-
Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
2015
-
ASSOCIATION OF BASELINE CORTICOSTEROID WITH OUTCOMES IN A MULTIVARIATE ANALYSIS OF THE PHASE 3 AFFIRM STUDY OF ENZALUTAMIDE (ENZA), AN ANDROGEN RECEPTOR SIGNALING INHIBITOR (ARSI)
2012
-
ASSOCIATION OF PROGRESSION BY PROSTATE CANCER WORKING GROUP (PCWG)-2 CRITERIA AND SURVIVAL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER
2012
-
OPENACT: PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
2012
-
SURVIVAL AMONG METASTATIC COLORECTAL CANCER (MCRC) PATIENTS TREATED IN A RANDOMIZED CONTROLLED TRIAL (RCT) VS AN OBSERVATIONAL COHORT STUDY (OCS)
2012
-
TASQUINIMOD MECHANISM OF ACTION BIOMARKERS: CORRELATION WITH PFS AND SURVIVAL IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER TREATED IN A RANDOMIZED PHASE 2 TRIAL
2012
-
PATIENT PREFERENCES FOR REDUCING TOXICITIES OF TREATMENTS FOR GASTROINTESTINAL STROMAL TUMOR (GIST): A CONJOINT ANALYSIS STUDY
2010
-
PATIENT PREFERENCES FOR TARGETED AGENTS IN RENAL CELL CARCINOMA (RCC): A BENEFIT RISK CONJOINT STUDY
2010
-
FOUR POLYMORPHISMS IN CYTOCHROME P450 1B1 (CYP1B1) GENE AND BREAST CANCER RISK: A META-ANALYSIS
2010
-
A pilot study of myeloablative (MA) autologous stem cell (AutoSCT) followed by reduced intensity allogeneic transplantation (RI AlloSCT) in children with poor risk Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL)
2008
-
Ovarian ablation or ovarian suppression versus chemotherapy for hormone receptor positive operable breast cancer: A meta-analysis
2007
-
Trastuzumab with adjuvant chemotherapy for resectable breast cancer: A meta-analysis
2007
-
Novel anticancer drugs TLR9 agonists act by interfering with EGFR and VEGF signalling and synergize with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts
2006
-
Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC)
2006
-
Phase II trial of sorafenib (bay 43-9006) in malignant mesothelioma: CALGB 30307
2006
-
Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633
2004
-
Immunotherapy of cancer with dendritic cell-based tumor vaccines
1998